ALSO NOTED: Daiichi Sankyo invests in venture fund; ImaRx sets IPO terms; and much more...

> Daiichi Sankyo plans to invest $60 million into a $180 million, 10-year venture fund run by Kearney Venture Partners. The deal allows Daiichi to strike collaborations with the biotech companies who gain funds from the venture group. Release

> ImaRx Therapeutics has set the terms of its IPO of 5 million shares at $10 to $12 each. Much of the $49 million the company hopes to net will go to product development and debt repayment. Report

> Trimeris of Morrisville, NC and Roche have extended their research pact for two distinct peptide classes. Report

> Barr Pharmaceuticals has filed a new offer in the bidding war for Pliva. Report

> The board of Discovery Partners International has approved a four-to-one stock split linked to its merger with Infinity Pharmaceuticals. Report

> Labopharm is preparing to unveil new Phase III safety data for tramadol that it says will support its effort to gain approvals for the pain therapy. Release

And Finally... A new study from Mount Sinai Medical Center resolves any lingering doubt that may exist about the link between the dust kicked up by the World Trade Center attack and persistent illnesses suffered by rescue workers. Article

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.